Added to YB: 2026-04-17
Pitch date: 2026-04-15
HNSA.ST [neutral]
Hansa Biopharma AB (publ)
-0.68%
current return
Author Info
No bio for this author
Company Info
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe.
Market Cap
SEK 3.0B
Pitch Price
SEK 29.36
Price Target
N/A
Dividend
N/A
EV/EBITDA
-6.41
P/E
-4.55
EV/Sales
14.78
Sector
Biotechnology
Category
turnaround
Hansa Biopharma: In-depth analysis
HNSA.ST (deep dive): Swedish biotech w/ imlifidase rapidly cleaving IgG antibodies for kidney transplants (EU since 2020) & autoimmune diseases. New CEO Renée Aguiar-Lucander (ex-Calliditas) cut costs, raised ~SEK 1B. Positive ph3 data in US kidney tx; FDA decision Dec 2026 (~90%+ approval odds). US TAM ~$1.4B vs EU €700M. Expects EU ops CF+ 2026, co-wide EBIT+ mid-2028. Anti-GBM ph3 missed endpoint but GBS ph2 promising; next-gen HNSA-5487 enables repeat dosing. Gene therapy deals w/ Sarepta (up to $397M milestones) & Genethon. Risks: FDA denial/delay, commercialization sluggishness, financing needs (modeled SEK 500M raise 2027). Trades 4.7x 2028e P/S vs peers; M&A potential post-US launch.
Read full article (26 min)